KPV Capsule (500mcg)

KPV Capsule (500mcg) — Research Overview

KPV (500mcg) is a research-grade tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-MSH, formulated in capsule format for laboratory research protocols examining intracellular signaling and cytokine regulation pathways. The capsule provides a consistent unit dose for oral administration research models.

What the Research Shows

KPV has been documented to cross cell membranes and interact with intracellular targets including NF-kB p65 nuclear translocation in intestinal epithelial cell models. This cell-penetrating activity distinguishes KPV from surface-receptor-only anti-inflammatory peptides. Preclinical mucosal tissue models have examined KPV’s effects on IL-8 and TNF-alpha cytokine production in inflammatory conditions. KPV has also been studied in combination with BPC-157 in multi-peptide research formats, given the mechanistic complementarity between KPV’s intracellular signaling effects and BPC-157’s angiogenic activity.

KPV is not approved by the FDA for human or veterinary therapeutic use. Human clinical trial data does not exist. All findings are preclinical.

Quality Documentation

• 99%+ purity — HPLC and Mass Spectrometry verified
• 500mcg KPV per capsule
• Batch-specific COA included with every order
• USA tested and fulfilled

For laboratory research purposes only. Not for human or veterinary consumption.